GlaxoSmithKline PLC
10 February 2003
Change in responsibilities of Board members
The Board of GlaxoSmithKline has reviewed the roles and responsibilities of the
company's Non-Executive Directors. Consequently, the following appointments have
been made, taking advantage of the skills and breadth of experience of the
company's Directors. The changes took effect from 7th February 2003:
Nominations Committee
Sir Ian Prosser has been appointed Chairman of the Nominations Committee
in place of Sir Christopher Hogg who will remain a member of the
Committee.
Remuneration Committee
Sir Peter Job has been appointed a member of the Remuneration Committee.
Corporate Social Responsibility Committee
Mr Donald McHenry has been appointed Chairman of the Corporate Social
Responsibility Committee in place of Sir Christopher Hogg who will
remain a member of the Committee.
S M Bicknell
Company Secretary
10th February 2003
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.